CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Co-founder and CEO of 10x Genomics. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...

Serge Saxonov, PhD, 10x Genomics co-founder and CEO 10x’s co-founder and CEO Serge Saxonov, PhD, says the company’s priorities for 2025 include promoting the new products it launched in 2024 ...

This collaboration will use 10x Genomics' Chromium GEM-X technology ... sets at low costs," said Gilad Almogy, Founder and CEO of Ultima Genomics. "Initiatives like the Billion Cells Project ...

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...